The authors of November's Clinical Case Study provided us with three exclusive questions that will not appear in the published version of the Case. We'd love to hear your answers to these questions in the comments section.

1) What does the literature suggest about the clinical utility of 3-methoxytyramine?

2) Do urinary free metanephrines offer any advantage over deconjugated total fractionated urinary metanephrines? And why is this so?

3) How does dialysis/renal failure affect plasma metanephrine levels?

Would you like to receive these Clinical Case Studies student discussions a month before they publish via email? Send an email with the subject 'subscribe' to and we will add you to the list